RT Journal Article
SR Electronic
A1 Buckley, Rita
T1 Exenatide Once Weekly Sustained Improvement in Glycemic Control with Weight Loss through 4 Years
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 16
SP 13
OP 14
DO 10.1177/155989771216004
UL http://mdc.sagepub.com/content/12/16/13.abstract
AB The once-weekly formulation of exenatide, a glucagon-like peptide-1 receptor agonist, is associated with clinically sustained improvement in glycemic control, continued improvements in cardiometabolic risk factors and weight loss after 4 years of treatment in type 2 diabetes mellitus (T2DM) patients. This article discusses results of the open-label extension of the Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects with Type 2 Diabetes Mellitus [DURATION-1; NCT00308139] clinical trial.